Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$9.9B
27M shares
52-week range
$236.73 – $396.23
83% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NYSE
CS
P/S (TTM)
3.8
EV / FCF (TTM)
29.9
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
www.bio-rad.comNo one on the platform currently holds BIO.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 1,684 | $469.4K |
No one on the platform has traded BIO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 2.4% | — | — | — | ||
| Rev. Growth % | 0.7% | 0.3% | ||||
| Profit Margin % | 29.4% | -10.0% | 19.8% | |||
| Free Cash Flow Margin % | 14.5% | 10.8% | 9.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +2.4% on the P/E track.
At today's price, your expected annual return is +7.7% on the P/E track.
At today's price, your expected annual return is +12.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.6B | +0.2% | $9.64 | $9.19–$10.09 | 38.2× | 2 |
| 2027 | $2.7B | +2.9% | $10.35 | $10.18–$10.50 | 35.6× | 2 |
| 2028 | $2.7B | +3.1% | $11.23 | $10.88–$11.41 | 32.8× | 1 |
| 2029 | $2.8B | +2.9% | $12.40 | $12.01–$12.60 | 29.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $1.75 | $2.62 | +49.7% |
| 2026-04-30 | $1.97 | $1.89 | -4.1% |
| 2026-02-12 | $2.57 | $2.51 | -2.3% |
| 2025-10-29 | $2.30 | $2.26 | -1.7% |
| 2025-07-31 | $1.93 | $2.61 | +35.2% |
| 2025-05-01 | $1.73 | $2.54 | +46.8% |
| 2025-02-13 | $2.86 | $2.90 | +1.4% |
| 2024-10-30 | $1.28 |
| $2.01 |
| +57.0% |
| $12.2B |
| — |
| GMEDGlobus Medical, Inc. | $75.77 | +2.13% | $10.2B | — |
| GRFSGrifols, S.A. | $7.48 | -0.93% | $6.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$IMDX At first glance I'm not a fan of this report: no $BIO agreement detail, no registry site update numbers, and no Q3 IQ kit sales. They wouldn't newly announce the heart KOL event if they weren't confident in the timeline and imminent approval, though. Tomorrow's price depends so much on Josh and Andrea's sentiment during this call
View on StockTwits ↗
$BIO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $13.89 up 19.02% YoY • Reported revenue of $651M down -0.09% YoY
View on StockTwits ↗$IMDX I try not to think too much into this, but I think reiterating 8/10 for the 10-Q is good news. They haven't been to any investor conferences for over a quarter now implicating the "quiet period" before the decision and $BIO agreement, but now they are the day after earnings... Why would I want to do a 1x1 if there's no news and they can't talk about the FDA timeline? Doesn't make sense, so I'm leaning bullish on the report and imminent approval, on track to 8/20 or even earlier. I'm not buying more before the readout as it's such a frizzy thought, though
View on StockTwits ↗
$BIO Share Price: $282.01 Contract Selected: Dec 18, 2026 $290 Calls Buy Zone: $23.20 – $28.67 Target Zone: $37.07 – $45.30 Potential Upside: 51% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
$D $TE $BIO $REGN https://factsheets.com/todays-top-volume-stocks-may-18-2026-t1-energy-surges-nextera-buys-dominion-nvda-eyes-earnings/
View on StockTwits ↗
Bio-Rad Laboratories, Inc. ( $BIO ) SpicyTrade - Daily Stock Analysis https://youtu.be/qAodwuw3aWI?si=DJytoGU4aTyYjkK3
View on StockTwits ↗
$BIDU $BRC $RAMP $D $BIO PRE-MARKET MOVERS: Currently Higher After Earnings: - Baidu (BIDU) up 4.6% - Brady (BRC) up 7.6% Currently Also Higher: - LiveRamp (RAMP) up 27.2% after Publicis (PUBGY) entered into an agreement to acquire the company for a total enterprise value of $2.2B - Dominion (D) up 13.7% after NextEra Energy and the company announced that they have entered into a definitive agreement to combine in an all-stock transaction - Bio-Rad Laboratories (BIO) up 7.5% after The Wall Street Journal reported activist investor Elliot Investment Management has built a big stake in the company - Ford (F) up 6.0% after the company and EDF Group announced the signing of a five-year framework agreement under which EDF power solutions will have the ability to procure up to four gigawatt hours of DC Block battery energy storage systems annually, representing a total potential volume of up to 20 GWh over the term of the agreement - Macy's (M) and Delta Air Lines (DAL) up 3.4% and 2.5%, respectively, after Berkshire Hathaway disclosed new positions in the companies Currently Lower After Earnings: - Gossamer Bio (GOSS) down 14.7% - Pioneer Power (PPSI) down 8.3% - iQiyi (IQ) down 2.5% - Soluna Holdings (SLNH) down 3.2% Currently Also Lower: - Regeneron (REGN) down 12.2% after reporting its fianlimab trial did not meet the primary endpoint - NextEra Energy (NEE) down 2.4% after the company and Dominion (D) announced that they have entered into a definitive agreement to combine in an all-stock transaction
View on StockTwits ↗
$BIO (+7.8% pre) Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad - WSJ https://ooc.bz/l/102663
View on StockTwits ↗
Elliott bought into $BIO to boost its weak stock, betting on turnaround and its valuable Sartorius stake driving future growth. https://notreload.xyz/xy/elliott-takes-stake-in-bio-rad-pushes-for-turnaround/
View on StockTwits ↗$BIO Bullish Piercing Candlestick Pattern Formed at Downtrend. Wait for the confirmation from the next day's candle.
View on StockTwits ↗
$BIO Great piece that accurately captures BIO's current position. So if you want to refresh your understanding of BIO or learn about BIO for the first time, this is essential reading. https://everyticker.com/quote/BIO/analysis/bio-rad-s-ddpcr-gambit-can-innovation-outrun-execution-headwinds-nyse-bio
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.